PHAR
Income statement / Annual
Last year (2024), Pharming Group N.V.'s total revenue was $297.20 M,
an increase of 21.15% from the previous year.
In 2024, Pharming Group N.V.'s net income was -$11.84 M.
See Pharming Group N.V.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$297.20 M |
$245.32 M |
$205.62 M |
$198.87 M |
$212.17 M |
$189.39 M |
$154.58 M |
$107.52 M |
$16.69 M |
$11.84 M |
| Cost of Revenue |
$35.40 M
|
$25.21 M
|
$17.56 M
|
$21.14 M
|
$23.54 M
|
$23.93 M
|
$25.37 M
|
$14.93 M
|
$4.93 M
|
$5.25 M
|
| Gross Profit |
$261.80 M
|
$220.10 M
|
$188.06 M
|
$177.73 M
|
$188.64 M
|
$165.46 M
|
$129.20 M
|
$92.59 M
|
$11.77 M
|
$6.59 M
|
| Gross Profit Ratio |
0.88
|
0.9
|
0.91
|
0.89
|
0.89
|
0.87
|
0.84
|
0.86
|
0.7
|
0.56
|
| Research and Development Expenses |
$83.15 M
|
$68.91 M
|
$52.53 M
|
$70.37 M
|
$38.52 M
|
$31.79 M
|
$33.04 M
|
$22.38 M
|
$16.18 M
|
$15.50 M
|
| General & Administrative Expenses |
$92.08 M
|
$80.68 M
|
$62.44 M
|
$46.38 M
|
$13.40 M
|
$11.16 M
|
$13.98 M
|
$7.17 M
|
$4.88 M
|
$4.09 M
|
| Selling & Marketing Expenses |
$7.14 M
|
$6.82 M
|
$6.41 M
|
$1.75 M
|
$51.60 M
|
$44.72 M
|
$39.51 M
|
$37.70 M
|
$3.19 M
|
$1.19 M
|
| Selling, General & Administrative Expenses |
$99.22 M
|
$87.50 M
|
$68.85 M
|
$48.13 M
|
$65.00 M
|
$55.88 M
|
$53.49 M
|
$44.86 M
|
$8.07 M
|
$5.28 M
|
| Other Expenses |
$88.06 M
|
$69.08 M
|
$48.44 M
|
$45.67 M
|
$8.86 M
|
$9.55 M
|
-$684.00 K
|
-$790.00 K
|
-$335.00 K
|
-$147.00 K
|
| Operating Expenses |
$270.42 M
|
$225.49 M
|
$169.83 M
|
$164.17 M
|
$112.38 M
|
$97.22 M
|
$85.74 M
|
$66.30 M
|
$23.91 M
|
$20.62 M
|
| Cost And Expenses |
$305.82 M
|
$250.70 M
|
$187.39 M
|
$185.31 M
|
$135.92 M
|
$121.14 M
|
$111.12 M
|
$81.23 M
|
$28.83 M
|
$25.87 M
|
| Interest Income |
$5.72 M
|
$3.53 M
|
$85.00 K
|
$52.92 K
|
$715.00 K
|
$1.13 M
|
$20.59 K
|
$3.60 K
|
$5.26 K
|
$130.10 K
|
| Interest Expense |
$8.74 M
|
$5.96 M
|
$5.36 M
|
$6.18 M
|
$5.94 M
|
$13.35 M
|
$16.37 M
|
$21.28 M
|
$3.77 M
|
$981.79 K
|
| Depreciation & Amortization |
$16.07 M
|
$15.93 M
|
$13.19 M
|
$19.61 M
|
$8.31 M
|
$5.80 M
|
$7.50 M
|
$4.10 M
|
$795.09 K
|
-$716.11 K
|
| EBITDA |
$16.32 M |
$9.88 M |
$33.53 M |
$48.78 M |
$58.35 M |
$71.46 M |
$50.98 M |
-$39.81 M |
-$13.88 M |
-$14.75 M |
| EBITDA Ratio |
0.05
|
0.04
|
0.16
|
0.25
|
0.28
|
0.38
|
0.33
|
-0.37
|
-0.83
|
-1.25
|
| Operating Income Ratio |
-0.03
|
-0.02
|
0.09
|
0.07
|
0.36
|
0.36
|
0.28
|
0.24
|
-0.73
|
-1.19
|
| Total Other Income/Expenses Net |
$129.00 K
|
-$6.63 M
|
-$3.25 M
|
$9.52 M
|
-$32.16 M
|
-$15.94 M
|
-$37.01 M
|
-$129.09 M
|
-$6.31 M
|
$4.07 M
|
| Income Before Tax |
-$8.49 M
|
-$12.01 M
|
$14.99 M
|
$23.08 M
|
$44.09 M
|
$52.30 M
|
$980.32 K
|
-$107.25 M
|
-$18.44 M
|
-$10.89 M
|
| Income Before Tax Ratio |
-0.03
|
-0.05
|
0.07
|
0.12
|
0.21
|
0.28
|
0.01
|
-1
|
-1.1
|
-0.92
|
| Income Tax Expense |
$3.35 M
|
-$1.46 M
|
$1.31 M
|
$7.08 M
|
$6.35 M
|
$11.75 M
|
-$27.61 M
|
-$11.33 M
|
$0.00
|
$851.68 K
|
| Net Income |
-$11.84 M
|
-$10.55 M
|
$13.67 M
|
$16.00 M
|
$37.75 M
|
$40.56 M
|
$28.59 M
|
-$95.92 M
|
-$18.44 M
|
-$10.89 M
|
| Net Income Ratio |
-0.04
|
-0.04
|
0.07
|
0.08
|
0.18
|
0.21
|
0.18
|
-0.89
|
-1.1
|
-0.92
|
| EPS |
-0.17 |
-0.14 |
0.17 |
0.2 |
0.47 |
0.52 |
0.35 |
-1.54 |
-0.35 |
-0.22 |
| EPS Diluted |
-0.17 |
-0.14 |
0.16 |
0.18 |
0.47 |
0.48 |
0.35 |
-1.54 |
-0.35 |
-0.22 |
| Weighted Average Shares Out |
$68.92 M
|
$65.70 M
|
$82.54 M
|
$87.64 M
|
$79.88 M
|
$84.19 M
|
$81.69 M
|
$62.55 M
|
$51.92 M
|
$51.09 M
|
| Weighted Average Shares Out Diluted |
$68.92 M
|
$65.70 M
|
$84.28 M
|
$87.64 M
|
$80.98 M
|
$84.19 M
|
$81.69 M
|
$62.55 M
|
$51.92 M
|
$51.09 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
